NCT06970119View on ClinicalTrials.gov

A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

May 9, 2025

Primary Completion Date

June 20, 2029

Study Completion Date

October 22, 2029

Conditions
Prostate Cancer
Interventions
DRUG

INR102 injection

INR102 injection is a lutetium-177 (\[177Lu\])-labeled radiopharmaceutical agent targeting prostate-specific membrane antigen (PSMA). It is clinically indicated for the treatment of patients with PSMA-positive prostate cancer.

Trial Locations (1)

300000

Tianjin Cancer Hospital Airport Hospital, Tianjin

All Listed Sponsors
lead

Yunhe Pharmaceutical (Tianjin) Co., Ltd

OTHER

NCT06970119 - A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter